Gilead Sciences (GILD) Debt to Equity (2008 - 2026)
Gilead Sciences (GILD) debt to equity from Dec 31, 2008 to Mar 31, 2026. The current Gilead Sciences (GILD) debt to equity is 94.30%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Gilead Sciences (GILD)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 109.84% | -20.51% |
| 2024 | 138.18% | +26.27% |
| 2023 | 109.43% | -7.87% |
| 2022 | 118.79% | -6.25% |
| 2021 | 126.70% | -26.56% |
| 2020 | 172.52% | +58.01% |
| 2019 | 109.18% | -14.54% |
| 2018 | 127.75% | -22.14% |
| 2017 | 164.08% | +17.63% |
| 2016 | 139.49% | +17.22% |
| 2015 | 119.00% | +47.99% |
| 2014 | 80.41% | +37.77% |
| 2013 | 58.36% | -33.98% |
| 2012 | 88.41% | -21.67% |
| 2011 | 112.86% | +923.91% |
| 2010 | 11.02% | +12455.14% |
| 2009 | 0.09% | -33.37% |
| 2008 | 0.13% | N/A |
Comparison Gilead Sciences (GILD) debt to equity with competitors
Gilead Sciences (GILD) debt to equity is 94.30%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -70.84% |
| BIIB | Biogen Inc | 33.72% | -64.25% |
| JNJ | Johnson & Johnson | 67.73% | -28.17% |
| PFE | Pfizer Inc | 71.50% | -24.17% |
| AZN | Astrazeneca plc | 71.66% | -24.01% |
| NVO | Novo Nordisk | 72.09% | -23.55% |
| GSK | GSK Plc | 106.74% | +13.20% |
| MRK | Merck & Co Inc | 107.06% | +13.53% |
| NVS | Novartis AG | 122.03% | +29.41% |
| LLY | Lilly(Eli) & Company | 139.02% | +47.42% |
| MDCX | MDCorp | 176.75% | +87.44% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | +87.44% |
| GRFS | Grifols SA | 177.15% | +87.87% |
| BMY | Bristol-Myers Squibb Company | 219.95% | +133.25% |
| AMGN | AMGEN Inc | 623.75% | +561.48% |
| OGN | Organon & Company | 948.95% | +906.34% |